Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

January 8, 2021January 8, 2021

FDA Approval Sought for Cilta-cel CAR T-cell Therapy

News

Janssen and Legend Biotech are seeking U.S. approval for their investigational CAR T-cell therapy ciltacabtagene autoleucel — known as cilta-cel — to treat adults with relapsed or refractory (hard-to-treat) ... Read more

December 14, 2020December 14, 2020

MMRF Joins Dana-Farber to Advance Research in Smoldering Myeloma

News

The Multiple Myeloma Research Foundation (MMRF) has joined forces with the Dana Farber Cancer Institute to develop new biomarkers and treatments for people with smoldering multiple myeloma (SMM) — a precursor condition to multiple ... Read more

October 30, 2020October 30, 2020

CLR 131 Elicits Promising Response Rates in Triple-refractory Multiple Myeloma Trial

News

CLR 131, Cellectar Biosciences’ lead experimental candidate, resulted in a 40% response rate among people with multiple myeloma who failed to respond to three treatment modalities, according to additional ... Read more

October 26, 2020October 26, 2020

Darzalex Delays Disease Progression After ASCT, Phase 3 Trial Reports

News

First-line maintenance therapy with Darzalex (daratumumab) significantly delays disease progression or death in adults with multiple myeloma who responded to autologous stem cell transplant (ASCT), according to data from the CASSIOPEIA trial’s second part. These ... Read more

September 25, 2020September 25, 2020

Ninlaro Combo Fails to Halt Progression of Newly Diagnosed Multiple Myeloma, Trial Data Show

News

Adding Takeda’s Ninlaro (ixazomib) to Revlimid (lenalidomide) and dexamethasone failed to significantly extend life without disease progression in people newly diagnosed with multiple myeloma who are ineligible for autologous ... Read more

September 1, 2020September 1, 2020

Cilta-cel, CAR T-cell Treatment, Named Breakthrough Therapy in China

News

Legend Biotech and Janssen’s investigational CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) has been given breakthrough therapy designation in China as a potential treatment of relapsed or refractory multiple myeloma. ... Read more

August 24, 2020August 24, 2020

FDA Approves Darzalex Triple Combo for Advanced Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Kyprolis (carfilzomib) and dexamethasone, to treat adults with relapsed or refractory multiple myeloma after one to three lines of therapy. Specifically, Darzalex ... Read more

August 10, 2020August 11, 2020

Ide-cel Application Resubmitted to FDA With Requested Data

News

Bristol Myers Squibb and Bluebird Bio have resubmitted a biologics license application (BLA) with additional information requested by the U.S. Food and Drug Administration to consider the approval of idecabtagene vicleucel (ide-cel) for adults with hard-to-treat multiple ... Read more

July 29, 2020July 29, 2020

First Patient Dosed in Trial Testing Belantamab Mafodotin, Nirogacestat Combo in RRMM Patients

News

A Phase 1b clinical trial evaluating GlaxoSmithKline (GSK)’s belantamab mafodotin, in combination with SpringWorks Therapeutics’ nirogacestat, in people with relapsed or refractory multiple myeloma, has dosed its first patient, SpringWorks ... Read more

July 27, 2020September 21, 2020

EU Approval Urged for GSX’s Belantamab Mafodotin for Heavily Treated Myeloma

News

GlaxoSmithKline’s investigational therapy belantamab mafodotin has been recommended for approval in the European Union, by the Committee for Medicinal Products for Human Use (CHMP), for heavily treated multiple myeloma ... Read more